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Summary.-The incidence of oncofoetal antigens has been reported to be increased in
patients with gynaecological cancers. In this study the incidence of CEA, AFP, and
hCG (, subunit) were studied in patients with adenocarcinoma of the ovary,
adenocarcinoma of the cervix, and squamous-cell carcinoma of the cervix. Using
a low cut-off point (CEA 2 5 ,ug/l, AFP 5 ,ug/l, and hCG 3 i.u./l) there is an unaccept-
ably high proportion of control patients having one or more positive tests (42-54%)
compared to cancer-bearing patients (67%). The specificity of the tests can be
increased to over 95°, by increasing the cut-off point to CEA 10 ug/l,AFP 10,g/I,
and hCG 10 i.u./l). Although this reduces the sensitivity considerably, the incidence of
false positives in the control population is reduced to nil in non-cancer patients and
to 2% in cancer patients tested when free of tumour, compared to 17% of patients
with cancer of the ovary, 330% with adenocarcinoma of the cervix, and 6% with
squamous-cell carcinoma of the cervix. Patients with adenocarcinoma of the cervix
were clearly distinguishable from those with squamous-cell carcinoma of the cervix
by these tests. There was also a significant correlation between AFP and hCG levels
in adenocarcinoma of the cervix (r=0 53, P<0.05).
SEVERAL ATTEMPTS have been made to
diagnose cancer using serological tech-
niques. More recently, the use of simul-
taneous assays has enabled the detection
ofahigherproportion ofpatients (Franchi-
mont et al., 1976; Coombes et al., 1980). In
gynaecological cancer, a numberofworkers
have looked for raised levels of various
cancer-relatedsubstanceswhichmaycorre-
late with tumour activity, including car-
cinoembryonic antigen (CEA), o-foeto-
protein (AFP), f subunit of human
chorionic gonadotropin (hCG), human
placental lactogen, isoenzymes, etc. (Sep-
pala et al., 1975; Fishman, et al., 1975;
Lin et al., 1975; Samaan et al., 1976;
Rutanen & Seppala, 1978; Khoo et al.,
1977, 1979a, b). In most of these studies,
the predictive value of these tests is not
clearly established. Moreover, in studies of
this nature the use of a control group of
patients is critical, since tumour markers
such as AFP and hCG may be under the
influence of hormones which may precede
tumour development and may be active
long after removal of the tumour. In this
study we examine the value of the onco-
foetal antigens (namely, CEA, AFP, and
hCG) in patients with cancer of the ovary,
squamous-cell carcinoma of the cervix,
and adenocarcinoma of the cervix, and
compare these findings with those in cancer
patients who have been free of tumour for
at least 1 year, as well as with age-matched
non-tumour-bearing patients.
MATERIALS AND METHODS
Patients
This study comprised 84 patients with
cancer of the ovary or cervix who were ex-
amined pre-operatively. There were 30
patients with cancer of the ovary, the histo-
logical diagnosis being serous adenocarcinoma
(11), endometrioid adenocarcinoma (6),
mucinous adenocarcinoma (4), mixed tumour
(4) and others (5). Most patients were inM. N. CAUCHI, S. H. KOH, D. LIM AND D. L. HAY
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cr for at least 1 year, were Missouri, U.S.A.). Serum (100 pl) orstandard
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hCG antiserum and 100 ul of 1251-labelled our control group, 24 age- hCGfor 18 h at room temperature(25TC). The
os with non-malignant gynae- bound fraction was separated by adding 2 ml
itons were studied The age of PEG (200 g/l, w/v) and the precipitate
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ye distribution in patients 0 11, 0-11, and 0 80% respectively. Inter- and
studied intra-assay coefficients of variation at 9-5
Age (years) i.u./l were 7-6% and 11.6% respectively. The Age (year) Asensitivity of the assay was 0-025 i.u./l.
-ratients iviean+s.ct. -Kange
Squamous-cell carcinoma of
cervix 57-4+14-7 24-83
Adenocarcinoma of cervix 52-2 + 14-7 33-77
Carcinoma of ovary 52-9 + 12-9 24-74
Tumour-free cancer patients 51-5+ 15-3 28-71
Controls 48-0 + 18-4 23-94
Blood 8amples
Samples from cancer patients were taken
before surgery or, in the case of cancer-free
patients, at follow-up clinics. The serum was
separated immediately and stored at -20°C
until assayed in a batch procedure.
Definitions*
Sensitivity=
diseased persons with positive test 100
all diseased subjects tested
Specificity=
nondiseased persons with negative test
all nondiseased subjects tested
x 100
* Vecchio, 1956.
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Positive predictive value (PV pos)=
number (or proportion) of diseased
persons with positive test x 100
total number (or proportion) of
persons with positive test
Negative predictive value (PV neg) =
number (or proportion of nondiseased
persons with negative test 100 total number (or proportion) of x
persons with negative test
RESULTS
The values of oncofoetal antigens in the
various cancer patients and control groups
are shown in Table III. There were marked
variations in all tests, rendering mean
values of little significance. Of more
relevance is the proportion of patients in
each group with high values.
CEA levels above 2-5 ,ug/l were found in
54% of all cancer-bearing patients, as well
as in 39% of tumour-free cancer patients
and 38% of non-cancer controls (Table
IV). When a cut-off point of 10 ,ug/l was
chosen, only 8% of cancer patients were
positive, compared to 2% of tumour-free
patients previously treated for cancer,
while none ofthe non-cancer control group
were positive. Patients with adenocar-
cinoma of the cervix had a higher fre-
quency ofhigh values.
AFP was > 5 ,ug/l in 10% of cancer
patients and in 4% ofnon-cancer controls.
When the cut-off point was increased to
10 ptg/l, 7% of the cancer patients had
high values, while none ofthe tumour-free
patients or the non-cancer control group
had high values. The highest percentage
of patients with high AFP was in the
group with adenocarcinoma of the cervix
(19%).
hCG was > 3 i.u./l in 20% of cancer
patients and in 27% of tumour-free
patients. Values of hCG > 10 i.u./l were
found in 5% of all cancer patients and in
none of the cancer-free patients or non-
cancer controls.
The proportion of patients with one or
more of these tests positive is shown in
Table V. When a low cut-off point was
used (i.e. CEA> 2-5 ,ug/l, AFP> 5 ,g/l,
hCG> 3 i.u./l, 67% of cancer patients
were found to be positive, but this was
not significantly different from tumour-
free cancer patients (54%) or the non-
tumour group (42%). Likewise, when the
cut-off point was slightly higher (viz.
CEA> 5 P,g/l, AFP> 10 jug/l, and hCG
> 10 i.u./l), the proportion of patients
with one or more positive tests was 15%
for the tumour-free cancer patients and
8% in the non-tumour group, compared
to 30% in the cancer patients. When the
cut-off point was raised even further
(CEA>10 ,ug/l, AFP>10 ,ug/l, and hCG
> 10 i.u./l), none of the control group had
high levels, compared to 17% of the
cancer-bearing group or 2% ofthe tumour-
free cancer patients. Patients with adeno-
carcinoma of the cervix were positive for
one or more tests more frequently (33%0)
than other cancer groups.
From the analysis of predictive values,
sensitivities, and specificities ofthese tests
(Tables IV & V), it can be seen that at
low cut-off points the specificity is very
poor, being about 61% for CEA and 46%
for multiple tests. However, when the
cut-off point for the various tests is raised,
the specificity is increased to >95%0. This
is associated with a marked reduction in
sensitivity (40-30%) and an associated
TABLE III.-Levels of oncofoetal antigens tn patients with gynaecological cancer
CEA (Ms Lgel) AFP (st.gel) hCG (i.u./R)
Patients Mean + s.d. Range Mean + s.d. Range Mean _s.d. Range
Squamous-cell carcinoma of cervix
(n =33) 4-4 + 7-2 0 9-43
Adenocarcinoma ofcervix (n = 21) 16-6 + 43-6 1-0-200
Carcinoma ofovary (n = 30) 15-8 + 66-9 0-9-369
Tumour-free cancer patients
(n=41) 4-3+ 10-9 0-9-72
Age-matched controls (n = 24) 2-3 + 1-6 0 9-7.5
1-7 + 1-5
40 + 6-5
3 7 + 10-9
0-2-7-0
0-2-20
0.1-60
2-2 + 3-2 0-2-18
3-0+ 4-7 0-2-19-9
30+73 01-41
1-8 + 1-8 0.1-10 2-2 + 1-7 0.1-6-4
1-8+1-3 10-6U0 1-6+0-6 10-34
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TABLE IV. Incidence ofoncofoetal antigens
CEA
> 2-5 ,ug/l
Predictive
No. Sensi- value
Total tive tivity -
No. tive (%) Pos. Neg.
Squamous-cell carcinoma
of cervix
Adenocarcinoma ofcervix
Carcinoma ofovary
Total cancer patients
Tumour-free cancer
patients
Non-cancer controls
Specificity
33
21
30
84
16
15
14
45
48
71
47
54
41 16 39
24 9 38
50
48
47
74
63
81
61
39
> 5-0 ,ug/l
Predictive
No. Sensi- value
posi- tivity
tive (%) Pos. Neg.
9
7
5
21
27
33
17
25
6 15
2 8
61
60
54
46
78
59
71
58
36
> 10 ,ug/l
A
Predictive
No. Sensi- value
posi- tivity .N
tive (%) Pos. Neg.
1
3
3
7
3
14
10
8
50
75
76
88
55
80
60
35
1 2
0 0
97 85
increase in the positive predictive value
from 43 to 87%.
It is of interest to note that there was a
positive significant correlation between
AFP and hCG levels in patients with
adenocarcinoma of the cervix (r = 0-53,
P> 0.05) but not in other tumours or
with other parameters. There was no
significant correlation between stage of
the disease and the proportion of patients
with high oncofoetal antigen levels.
DISCUSSION
The value of the detection of CEA in
gynaecological cancer has been subjected
to several studies. When a level of 2-5 ,ug/l
is taken as the cut-off point, an unaccept-
ably high false-positive rate is detected
in normal controls, e.g. 11% (Van Nagell
et al., 1975), 18% (Donaldson et al., 1980)
and 10% (Di Saia et al., 1977). When a
CEA level of 5,Lg/l is taken as the cut-off
point, the proportion ofpatients with high
levels varies from 63% in cancer of the
ovary (Khoo et al., 1977, 1979a, b; Sarjadi
et al., 1980), 31% of cases of cancer of the
corpus, 36% of patients with cancer of
the cervix, and 36% of cancer of the
ovary, compared to 0% in controls.
Rutanen et al. (1978), on the other hand,
found an incidence ofonly 9-8% in patients
with gynaecological cancer, with a maxi-
mal incidence in ovarian cancer (20%);
squamous-cell carcinoma had 10%, adeno-
carcinoma of the cervix 19%, and endo-
metrial carcinoma 7%. In our study we
find that, when a CEA value of 2-5 ptg/l
is taken as cut-off, 38% of controls have
high values, compared to 54% of cancer
patients. This figure is quite unacceptable.
When, however, a cut-off point of 10 ug/l
is taken, none of the control patients have
a high value, compared to 8% of cancer
patients. 14% of adenocarcinoma of the
cervix patients had high CEA lev-els,
compared to 3% with squamous-cell car-
cinoma. Moreover, in a previous study we
showed that in none of 36 patients with
cancer of the endometrium was CEA> 5
,ug/l (Cauchi et al., 1980). This is in agree-
ment with the findings of Franchimont
et al. (1976), Hansen et al. (1974), and Stone
et al. (1977), who emphasize theimportance
of taking CEA> 10 /xg/l as the cut-off
level.
AFP has also been investigated as a
possible tumour marker in gynaecological
cancer. Khoo et al. (1977) found that 17%
of 108 patients with cancer of the ovary
had AFP levels > 25 ,ug/l. In germ-cell
tumours the level was usually > 200 ,ug/l.
Donaldson et al. (1980) found values of
AFP > 20 ,ug/l in 52% of invasive cancers
(endometrial cancer 50%, ovarian cancer
57%, vulval cancer 43%, cervical cancer
53%). However, the finding that 22% of
control patients also have high AFP
cannot be readily explained. These authors
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hCG ~~~~~~~~A
> 5 ,ug/l
Predictive
No. Sensi- value
posi- tivity ,
tive (%) Pos. Neg.
1 3 50 56
4
3
8
1
19
10
10
2
80
75
89
70
60
35
4 -
98
> 10 jug/l
Predictive
No. Sensi- value
posi- tivity,
tive (%) Pos. Neg.
0 0 0 55
4
2
6
0
19
7
7
0
100
100
100
71
59
34
> 3 ,ug/l
Predictive
No. Sensi- value
posi- tivity
tive (%) Pos. Neg.
7 21 39 54
5
5
17
11
0 0 -
100
24
17
20
27
31
32
61
2 8 -
73
65
54
31
> 10 ig/l
A
Predictive
No. Sensi- value
posi- tivity
tive (%) Pos. Neg.
1 3 100 100
2
1
4
0
9
4
5
0
100
100
100
68
58
34
0 0
100
conclude that AFP levels were most often
high in large-cell non-keratinizing cancer,
as well as germ-cell or stromal tumours of
the ovary. Our studies show that none of
the control patients or the tumour-free
cancer patients had AFP levels > 10 /g/l,
whilst 7% of cancer-bearing patients had
high values.
Human chorionic gonadotropin (hCG)
has also been used as a marker of gynaeco-
logical cancer. Donaldson et al. (1980)
showed that a level ofhCG > 5.0 i.u./l was
found in 3% of controls and in 22% of
invasive gynaecological cancer, the highest
values being found in serous cystadeno-
carcinomas of the ovary and in patients
with keratinizing squamous-cell carcinoma
ofthe cervix. Likewise, Carenzaetal. (1980)
found that 44% of 18 patients with endo-
metrioid cancer and 7/17 (41%) with
ovarian cancer had detectable quantities
of hCG in their sera, mean hormone levels
being 28-4 i.u./l in ovarian cancer and
7-1 i.u./l in endometrioid cancer, and only
in 3/34 (8.8%) in benign disease of endo-
metrium or ovary. Although Franchimont
et al. (1976) consider level of hCG> 15
,ug/l to be abnormal, we find that 8% of
controls and 27% of tumour-free cancer
patients had values >3 i.u./l. However,
neither of these groups had levels > 10
i.u./l, whilst 5% of cancer patients had
TABLE V.-Proportion ofpatients with one or more positive tests at various cut-off levels*
Patient group (n)
Squamous-cell carcinoma
ofcervix (33)
Adenocarcinoma of
cervix (21)
Carcinoma of ovary (30)
Total cancer patients (84)
Tumour-free cancer
patients (41)
Non-cancer controls (24)
* Low
Intermediate
High
CEA
(.tg/l)
2 5
5*0
10-0
Low levels Intermediate levels High levels
A A , A ,
Predictive Predictive Predictive
No. Sensi- value No. Sensi- value No. Sensi- value
p osi- tivity p osi- tivity p osi- tivity
tive % Pos. Neg. tive % Pos. Neg. tive % Pos. Neg.
23 70 51 66
17
16
56
81
53
66
22 54
10 42
AFP
(.tg/l)
5
10
10
43
42
72
91
57
40
9 27 60 59
9
7
25
43
23
30
6 15
2 8
hCG Specificity
(i.U./I) ( %
3 46
10 85
10 98
60
54
81
85
60
37
2 6 67 56
7
5
14
33
17
17
87
83
93
74
61
17
- 1 2
0 0
inpatients with cancer ofthe ovary and cervix
AFP
f K
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values > 10 i.u./l. The standardization of
hCG estimations between the various
laboratories is, however, notoriously diffi-
cult to establish, and therefore comparison
between different laboratories may be
misleading.
The value of multiple tumour markers
to establish the diagnosis ofgynaecological
cancer depends also on the cut-off point
for these markers. A number of workers
have used a combination of CEA, AFP,
andhCGto detect the presence ofgynaeco-
logical cancer. Donaldson et al. (1980)
found that - 85% of gynaecological can-
cers have elevation ofone or more ofthese
cancer markers. However, the cut-off
point taken by these authors (CEA 2-5
Hg/l, hCG 5 0 i.u./l, and AFP 20 ,g/l) pro-
duced an unacceptably high level of false
positives in control patients (31%). This is
due to the relatively low cut-off point for
CEA and the unexplained high proportion
of control patients (22%) with AFP> 20
,ug/l. The reason for this high proportion
of AFP positive patients is not clear.
Seppala et al. (1975) measured these
markers in advanced ovarian cancer and
found high CEA in 21% of patients, only
one of whom had high AFP and none
raised hCG. Our data (Table V) show that,
while a low cut-off point for these markers
(namely CEA 2-5 ,ug/l, AFP 5 ,6gll,
hCG 3 i.u./l) results in an unacceptably
high false-positive rate in control patients
(42-54%),using ahighercut-offpoint(CEA
10 pg/l, AFP 10 ,ug/l, hCG 10 i.u./l) pro-
duced none of the control patients and
only 1/42 of tumour-free cancer patients
with one or more positive tests, compared
to 17% of cancer:bearing patients. Even
higher values (33%) were foundin patients
with adenocarcinoma of the cervix.
These studies emphasize the importance
of establishing the upper levels of normal,
not only for age-matched normal persons
but also for tumour-free cancer patients,
in view of the fact that factors, including
hormone stimulation, might be operating
in a cancer patient irrespective of the
presence or absence oftumour. The finding
that there is a significant correlation
between AFP and hCG in patients with
adenocarcinoma of the cervix would
indicate that production of these hormone
markers was the result of the same stimu-
lus, which is not necessarily the tumour
itself. Further studies of the relevance of
hormone stimulation to high oncofoetal
antigen levels are under way.
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